CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabineRaphaëlle Fanciullino, Régis Costello, Laure Farnault et al.|Blood Advances|2018Cited by 43
Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patientsMélanie Donnette, Raphaëlle Fanciullino, Joseph Ciccolini et al.|Journal of Chromatography B|2019Cited by 12
Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351Mélanie Donnette, Raphaëlle Fanciullino, Mourad Hamimed et al.|Journal of Controlled Release|2021Cited by 9
High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implicationsMélanie Donnette, Raphaëlle Fanciullino, Joseph Ciccolini et al.|Annals of Oncology|2021Cited by 8
Cytidine deaminase status as a marker of response to azacytidine treatment in <scp>MDS</scp> and <scp>AML</scp> patientsMélanie Donnette, Raphaëlle Fanciullino, Mourad Hamimed et al.|British Journal of Haematology|2023Cited by 4